Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7271-7280 Newer>

The Motley Fool March 25, 2011 Selena Maranjian	Make Money in Pharmaceuticals the Easy Way There's no need to guess which pharmaceutical company will perform best with the SPDR S&P Pharmaceuticals ETF.
The Motley Fool March 25, 2011 Brian Orelli	Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science.
The Motley Fool March 24, 2011 Brian Orelli	It's the Combo That Matters for Gilead The same efficacy with fewer pills is the headline, but it's the understory that makes Gilead Sciences' latest clinical trial success important for investors.
CIO February 7, 2011 Tom Kaneshige	iPad Security: How a Hospital Group Treated Trouble Take an inside look at how one hospital group is testing and perfecting its prescription for security as its doctors demand to do more work on iPads. One decision: Not all apps are ready yet.
The Motley Fool March 24, 2011 Anand Chokkavelu	Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund."
The Motley Fool March 23, 2011 Jordan DiPietro	Should You Buy and Hold Cardinal Health? Does this company have the traits of a good retirement stock?
The Motley Fool March 23, 2011 Brian Orelli	Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own.
The Motley Fool March 23, 2011 Todd Wenning	Dividend Report Card: Pfizer Investors considering Pfizer as a dividend play should decide if the combination of 4% current yield and low- to mid-single-digit dividend growth potential is a better deal than other pharmaceutical shares are offering.
The Motley Fool March 22, 2011 Brian Orelli	Pharmas in the Doghouse Merck and Sanofi call off their joint venture.
The Motley Fool March 21, 2011 Brian Orelli	Let's See Some Data, Curis Curis investors seem to have shrugged off the multiple unknowns and embraced the potential for the company's skin cancer drug.
<Older 7271-7280 Newer> Return to current articles.